Cargando…

Improved Quality of Life in Patients Treated with Peptide Radionuclides

Peptide receptor radionuclide therapy (PRRT) has recently been established as an important treatment modality for somatostatin receptor (SSTR)-positive tumors. The purpose of this study was to evaluate the clinical response, side-effects as well as the quality of life following (90)Y-DOTA-lanreotide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Traub-Weidinger, T, Raderer, M., Uffmann, M., Angelberger, P., Kurtaran, A., Leimer, M., Preitfellner, J., Dudczak, R., Virgolini, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227337/ https://www.ncbi.nlm.nih.gov/pubmed/22144870 http://dx.doi.org/10.4103/1450-1147.89779

Ejemplares similares

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
por: Raderer, M., et al.
Publicado: (1998)

Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
por: Raderer, M, et al.
Publicado: (2001)

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results
por: Raderer, M, et al.
Publicado: (1999)

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017)

Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.
por: Virgolini, I., et al.
Publicado: (1990)

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
por: Nilica, Bernhard, et al.
Publicado: (2016)

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.
por: Virgolini, I., et al.
Publicado: (1993)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
por: Chakraborty, Kushal, et al.
Publicado: (2023)

The Paradox of Using Radionuclides To Treat Disease
por: Albrecht-Schmitt, Thomas E.
Publicado: (2019)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor
por: Häfliger, Simon, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
por: Cimini, Andrea, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
por: Kumar, Amit, et al.
Publicado: (2022)

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule
por: Maaß, Christian, et al.
Publicado: (2016)

International Committee for Radionuclide Metrology Symposium on Radionuclide Metrology and its Applications
por: Bortel, G, et al.
Publicado: (1994)

Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer
por: Huynh, Truc T., et al.
Publicado: (2022)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Combination Strategies to Improve Targeted Radionuclide Therapy
por: Chan, Tiffany G., et al.
Publicado: (2020)

In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
por: Feijtel, Danny, et al.
Publicado: (2023)

Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
por: Bison, Sander M., et al.
Publicado: (2014)

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
por: Beukhof, Carolien M., et al.
Publicado: (2019)

Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity
por: Czepczyński, Rafał, et al.
Publicado: (2014)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

A Peptide Meets a Radionuclide to Combat a Rare Tumor
por: Thomas, Katharine E., et al.
Publicado: (2021)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
por: Luyten, Kaat, et al.
Publicado: (2021)

Quality of life and social contacts in old age
por: Loeffler, K, et al.
Publicado: (2022)

General Discussion on Medical Radionuclides
por: Qaim, S M
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n6h9r7idlt9o16sg53j9l2d7l8